Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 10/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NNMT | P40261 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30170611 | 1.00 | POLB (0.52) | POLBCASP1LMNAKEAP1NFE2L2 | |
| SCHEMBL21906152 | 0.86 | POLB (0.50) | POLBCASP1LMNASIRT3TDP1 | |
| SCHEMBL20298365 | 0.85 | POLB (0.49) | POLBCASP1LMNASIRT3TDP1 | |
| SCHEMBL1330488 | 0.82 | KEAP1 (0.60) | POLBLMNAKEAP1NFE2L2ALDH1A1 | |
| SCHEMBL566114 | 0.79 | CASP1 (0.47) | POLBCASP1LMNAKEAP1NFE2L2 | |
| SCHEMBL29406095 | 0.79 | CASP1 (0.47) | POLBCASP1LMNAKEAP1NFE2L2 | |
| SCHEMBL7579745 | 0.77 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL14554116 | 0.77 | CASP1 (0.42) | POLBCASP1LMNAKEAP1NFE2L2 | |
| SCHEMBL20194580 | 0.77 | CA12 (0.50) | POLBCASP1LMNASIRT3TDP1 | |
| SCHEMBL166218 | 0.76 | KEAP1 (0.69) | POLBCASP1LMNAKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-05-30 | — | — | US | disclosed |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2018217651-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180334454-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2018-11-22 | — | — | US | disclosed |
| US-9499570-B2 | Boron containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150376210-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2015-12-31 | — | — | US | disclosed |
| US-9145429-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140200198-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-8716478-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120035132-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| EP-0482481-A1 | Method for the preparation of 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepines | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1992-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | POLB 549/4885CASP1 3637/4885LMNA 2823/4885 |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | POLB 549/4885CASP1 3637/4885LMNA 2823/4885 |
| US-20140200198-A1 | BORON-CONTAINING SMALL MOLECULES | BTD, BCL6B, BBOX1 | POLB 2278/4885CASP1 275/4885LMNA 2417/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | POLB 549/4885CASP1 3637/4885LMNA 2823/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | POLB 549/4885CASP1 3637/4885LMNA 2823/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | POLB 549/4885CASP1 3637/4885LMNA 2823/4885 |
| US-20180334454-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | POLB 549/4885CASP1 3637/4885LMNA 2823/4885 |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | POLB 549/4885CASP1 3637/4885LMNA 2823/4885 |
| US-20120035132-A1 | BORON-CONTAINING SMALL MOLECULES | BTD, BCL6B, BBOX1 | POLB 2278/4885CASP1 275/4885LMNA 2417/4885 |
| US-20150376210-A1 | BORON-CONTAINING SMALL MOLECULES | BTD, BCL6B, BBOX1 | POLB 2278/4885CASP1 275/4885LMNA 2417/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | POLB 549/4885CASP1 3637/4885LMNA 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.